PAREXEL Introduces New Dedicated Division to Help Emerging Biotech Companies Reach their Goals Quickly and Cost-Effectively

January 7, 2019

Pharmaceutical Executive

PAREXEL, an innovator of global biopharmaceutical services, introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.

PAREXEL, an innovator of global biopharmaceutical services, introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.

PAREXEL Biotech combines the company’s expertise and global infrastructure with a model that is aligned to this specific segment, providing enhanced consulting and development capabilities through a new biotech-focused team and organizational structure. This team led by James Anthony and Graciela Racaro, will help emerging companies minimize complexity, reduce costs, and accelerate timelines through the use of many different strategies and services. Those services and strategies include global regulatory consulting, patient recruitment services, trial execution services, Real World Evidence programs, and much more.